<DOC>
	<DOCNO>NCT01261494</DOCNO>
	<brief_summary>This study expect demonstrate anti-diabetic efficacy 3-months treatment GFT505 ( 80 mg/d ) Glycosylated Haemoglobin A1c ( HbA1C ) fast plasma glucose . And assess tolerability safety once-a-day administration oral dos GFT505 12 week patient type 2 diabetes mellitus .</brief_summary>
	<brief_title>Study With GFT505 ( 80mg ) Versus Placebo Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>The study period per patient 16-20 week maximum conducted follow : - Run-in period : 2 week 6 week patient fibrate treatment screening ( 4 week fibrate wash-out + 2 week placebo run-in ) ; - Treatment period : 12 week ; - Follow-up period : 2 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male postmenopausal female ( define &gt; 12 month since last menstrual period ) surgical menopause . If hormonal replacement therapy , stable least 6 month prior screen . Body Mass Index ≥27 ≤45 kg/m² . DrugNaive patient type 2 diabetes mellitus ( non insulin dependent diabetes ) . Patients treat insulin diabetes medication last 3 month prior screen . Patients treat less 4 week insulin may include study . HbA1c ≥ 7.0 % &lt; 9.5 % . Antibody glutamate decarboxylase acid ( AntiGAD ) negative patient age less 40 year . Type I Diabetes Mellitus . Blood Pressure &gt; 160 / 95 mmHg . Lipidlowering drug fibrates . Fasting Plasma Glucose ( FPG ) ≥ 240 mg/dL . Triglycerides ( TG ) &gt; 400 mg/dL .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Glucose Metabolism Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>PPARs</keyword>
	<keyword>OGTT</keyword>
</DOC>